Daily administration of large doses of factor VIII concentrate in a hemophiliac with a high titer factor VIII inhibitor resulted in marked reduction in the titer and response of the inhibitor to factor VIII administration and made possible elbow and bilateral knee replacements under conventional factor VIII coverage. Studies performed during the course of treatment indicated that the reduction ...

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4kappa antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of...

A recombinant Factor VIII (Factor VIII-delta II) consists of a unique polypeptide chain of 165 kDa deleted from the major part of the B-domain and from the cleavage site at Arg-1648-Glu-1649 found in plasma-derived Factor VIII. It was expressed in mammalian cells in serum-free medium containing von Willebrand factor and purified by a one-step immunopurification. The recombinant Factor VIII was ...

To study the interaction between factor VIII and von Willebrand factor (vWF), binding experiments were performed using immobilized plasma vWF. Plasma was obtained from healthy donors and from patients with severe hemophilia A. For normal and hemophilic vWF, the dissociation constants (kd) for binding of factor VIII to vWF were 0.21 +/- 0.04 and 0.22 +/- 0.05 nmol/L, respectively. At saturation,...

Immunohistochemical localization of factor VIII-related antigen was studied in human tissues obtained at autopsy or renal biopsy, umbilical cord vessels, smears of washed blood cells and cultured human endothelial cells. Factor VIII-related antigen was demonstrated in the vascular intima throughout the body and cells lining the sinusoids of the lymph node, spleen and liver by an indirect immuno...

Two patients with hemophilia A and antiquential antibody titers demonstrated no factor VIII antibodies were treated with change in antibody response in either infusions of factor VIII concentrates and patient when compared to previous studintravenous cyclophosphamide in an aties following factor VIII infusion alone. tempt to suppress the antibody response. These results are in contrast to the p...

The development of an immune response to infused factor VIII is a complication affecting many patients with hemophilia A. Inhibitor antibodies bind to antigenic determinants on the factor VIII molecule and block its procoagulant activity. A patient-derived inhibitory immunoglobulin G4k antibody (BO2C11) produced by an immortalized memory B-lymphocyte cell line interferes with the binding of fac...

Pembelajaran IPA dikatakan berhasil jika semua tujuan pembelajaran yang telah ditetapkan dapat terpenuhi, ditunjukkan dengan hasil belajar IPA. Hasil dipahami sebagai dari proses mengajar digunakan untuk menentukan atau tidaknya suatu program pembelajaran. Penelitian ini bertujuan mengetahui ada perbedaan capaian siswa kelas VIII pada materi sistem pencernaan. penelitian dijadikan umpan balik b...

The gene for the coagulation protein factor VIII contains several common restriction fragment length polymorphisms which can be used to analyse the pattern of inheritance of factor VIII alleles within families. This can be exploited to identify carriers of haemophilia, an X-linked inherited disorder characterised by deficiency of factor VIII. In this study the polymerase chain reaction was used...

The present study reports on the treatment of bleeding episodes and the natural history of factor VIII inhibitors in 4 patients with acquired haemophilia A postpartum. Low titre type II factor VIII inhibitors in 3 patients and high titre type I inhibitor in 1 patient became apparent immediately to 7 months after delivery. High dose human factor VIII concentrate substitution was effective in con...